Transdermal composition containing selegiline
The invention concerns an anhydrous transdermal preparation comprising in a 20-100% lyotropic liquid crystalline arrangement: 5-15 w.% of optically active or racemic N-methyl-N-(phenyl-2-propyl)-2-propynylamine or N-methyl-N-(1-(4-fluoro-phenyl)-2-propyl)-2-propynylamine or their therapeutically acc...
Gespeichert in:
Hauptverfasser: | , , , , , , , , , |
---|---|
Format: | Patent |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext bestellen |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | The invention concerns an anhydrous transdermal preparation comprising in a 20-100% lyotropic liquid crystalline arrangement: 5-15 w.% of optically active or racemic N-methyl-N-(phenyl-2-propyl)-2-propynylamine or N-methyl-N-(1-(4-fluoro-phenyl)-2-propyl)-2-propynylamine or their therapeutically acceptable salts, 40-70 w.% of liquid polyoxyethyleneglycol, 10-20 w.% of solid polyoxyethyleneglycol, 2-30 w.% of a nonionic surface active agent, 2-20 w.% of propyleneglycol, if desired 0.5-2 w.% of a polymer the a value of which is > 0.6, and if desired other auxiliary agents. |
---|